LJ570

CAS No. 2252488-69-8

LJ570( —— )

Catalog No. M21635 CAS No. 2252488-69-8

LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 338 Get Quote
5MG 519 Get Quote
10MG 743 Get Quote
25MG 1134 Get Quote
50MG 1512 Get Quote
100MG 2061 Get Quote
500MG 4131 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LJ570
  • Note
    Research use only, not for human use.
  • Brief Description
    LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively.
  • Description
    LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively)
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2252488-69-8
  • Formula Weight
    394.5
  • Molecular Formula
    C27H22O3?
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antonio L Luca P Carmen C et al. Identification of the First PPARα/γ Dual Agonist Able to Bind to Canonical and Alternate Sites of PPARγ and to Inhibit its Cdk5-Mediated Phosphorylation[J]. Journal of Medicinal Chemistry 2018:acs.jmedchem.8b00835-.
molnova catalog
related products
  • Aleglitazar

    A potent and balanced dual PPARα/γ agonist (EC50= 50/21 nM).

  • SR1664

    SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity.

  • AZD 6610

    AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.